/
© 2026 RiffOn. All rights reserved.

Get your free personalized podcast brief

We scan new podcasts and send you the top 5 insights daily.

  1. Research To Practice | Oncology Videos
  2. Ovarian Cancer — Microlearning Activity 1: Proceedings from an Independent Satellite Symposium during the SGO Annual Meeting on Women's Cancer
Ovarian Cancer — Microlearning Activity 1: Proceedings from an Independent Satellite Symposium during the SGO Annual Meeting on Women's Cancer

Ovarian Cancer — Microlearning Activity 1: Proceedings from an Independent Satellite Symposium during the SGO Annual Meeting on Women's Cancer

Research To Practice | Oncology Videos · Oct 13, 2026

Experts evaluate frontline PARP inhibitor and bevacizumab maintenance strategies and criteria for PARP rechallenge in ovarian cancer.

Separate Indications for PARP Inhibitors and Bevacizumab Based on Clinical Risk Profiles

Clinicians separate maintenance indications instead of combining agents by default. Bevacizumab is selected for higher-risk biology, such as residual disease or ascites where angiogenesis dominates, whereas low-risk HRD-deficient patients can rely solely on PARP inhibitors to prevent unnecessary toxicity.

Ovarian Cancer — Microlearning Activity 1: Proceedings from an Independent Satellite Symposium during the SGO Annual Meeting on Women's Cancer thumbnail

Ovarian Cancer — Microlearning Activity 1: Proceedings from an Independent Satellite Symposium during the SGO Annual Meeting on Women's Cancer

Research To Practice | Oncology Videos·a month ago

Treat Exceptional Platinum Responders with PARP Inhibitors Despite Negative HRD Test Results

HRD status is a continuous variable with an arbitrary diagnostic cutoff rather than a strict binary result. When a patient achieves a complete pathological response to neoadjuvant platinum, clinicians consider PARP inhibitors even if formal genomic testing returned negative.

Ovarian Cancer — Microlearning Activity 1: Proceedings from an Independent Satellite Symposium during the SGO Annual Meeting on Women's Cancer thumbnail

Ovarian Cancer — Microlearning Activity 1: Proceedings from an Independent Satellite Symposium during the SGO Annual Meeting on Women's Cancer

Research To Practice | Oncology Videos·a month ago

Inconclusive HRD Genomic Results Often Signal Chemotherapy Eradication Rather Than Technical Failure

Inconclusive HRD assays frequently occur following neoadjuvant chemotherapy due to a lack of residual tumor tissue at interval debulking. Rather than indicating an assay failure, the absence of assessable tissue demonstrates an exceptional pathological response to initial systemic treatment.

Ovarian Cancer — Microlearning Activity 1: Proceedings from an Independent Satellite Symposium during the SGO Annual Meeting on Women's Cancer thumbnail

Ovarian Cancer — Microlearning Activity 1: Proceedings from an Independent Satellite Symposium during the SGO Annual Meeting on Women's Cancer

Research To Practice | Oncology Videos·a month ago

Reserve PARP Inhibitor Re-Challenge for BRCA Carriers with Long Platinum-Free Intervals

Clinicians consider PARP re-challenge primarily when progression occurs after a prolonged period off maintenance rather than during active therapy. Due to regulatory shifts and emerging practice patterns, repeat treatment is reserved for BRCA-mutated patients with preserved platinum sensitivity.

Ovarian Cancer — Microlearning Activity 1: Proceedings from an Independent Satellite Symposium during the SGO Annual Meeting on Women's Cancer thumbnail

Ovarian Cancer — Microlearning Activity 1: Proceedings from an Independent Satellite Symposium during the SGO Annual Meeting on Women's Cancer

Research To Practice | Oncology Videos·a month ago